癌症分析:全球市場預測(2022年∼2027年)

全球癌症分析的市場規模在2020年估算為177億5,000萬美金，在預測期間內預計將以15.67％的年複合成長率擴大，2027年成為491億7,600萬美元。

本報告提供癌症分析的世界市場調查，提供市場規模和預測，市場促進因素及課題，市場趨勢，各市場區隔的市場分析，競爭情形，主要企業的簡介等系統性資訊。

目錄

第1章 簡介

• 市場定義
• 市場區隔

第2章 調查手法

• 調查資料
• 假設

第3章 摘要整理

• 調查的重點

第4章 市場動態

• 推動市場要素
• 阻礙市場要素
• 波特的五力分析
  • 終端用戶談判力
  • 買方議價能力
  • 新加入廠商者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係
• 產業的價值鏈分析

第5章 全球癌症分析市場分析:各技術

• 簡介
• 免疫組織化學
• 原位雜交
• 下一代序列
• 定量的聚合酵素鏈鎖反應(qPCR)
• 質譜分析
• 微陣列
• 其他

第6章 全球癌症分析市場分析:癌症各類型

• 簡介
• 乳癌
• 肺癌症
• 結腸直腸癌症
• 前列腺癌症
• 黑色素瘤癌症
• 腎臟癌症
• 肝臟癌症
• 其他

第7章 全球癌症分析市場分析:各用途

• 簡介
• 個人化醫療
• 腫瘤學的診斷
• 癌症調查
• 生物標記的發現
• 治療和監測
• 其他

第8章 全球癌症分析市場分析:各地區

• 簡介
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 南美
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

第9章 競爭環境與分析

• 主要企業策略分析
• 新興企業和市場收益性
• 合併，收購，協定，及合作
• 供應商競爭力矩陣

第10章 企業簡介

• Illumina, Inc.
• Qiagen N.V.
• NeoGenomics Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Genomic Health
• GE Healthcare
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Hologic Inc.
• Bio-Rad Laboratories Inc.

The global cancer profiling market is expected to grow at a compound annual growth rate of 15.67% over the forecast period to reach a market size of US$49.176 billion in 2027 from US$17.750 billion in 2020.

Cancer is generally defined as uncontrolled cell proliferation that has the potential to be fatal. Environmental factors are the most common source of changes in gene encoding that prompt cell regulation. Cell mutation causes aberrant cell proliferation, affecting adjacent cells and organs. Cancer or tumour profiling is a diagnostic technique that looks for specific genes or gene mutations (changes), proteins, or other biomarkers in tumour tissue samples. Tumour profiling may be used to aid treatment planning and to predict whether cancer will recur or spread to other areas of the body.

The major growth factors for this market are the rising global prevalence of cancer and the increasing use of biomarkers in tumour profiling. Increased cancer research and funding initiatives, as well as technical developments in profiling technologies, are also driving the growth of the cancer profiling market. Furthermore, the growing demand for personalised medicine and point-of-care diagnostics is projected to provide substantial potential possibilities for market participants throughout the forecast period.

On the other hand, high capital investment, high procedure costs, and concerns regarding technical difficulties with sample collection and storage are likely to hinder the expansion of the cancer tumour profiling market. Poor regulatory standards and reimbursement options, as well as a low discovery-to-approval ratio, are expected to provide challenges to the cancer profiling market.

The global cancer profiling market is expected to be dominated by the North American region. The number of cancer patients in the United States has increased significantly. According to the American Cancer Society, there will be an estimated 1,898,160 new cancer cases and 608,570 cancer deaths in the United States in 2021, which is approximately 5,200 new cases and 1,670 deaths per day. Breast cancer, lung and bronchus cancer, prostate cancer, colorectum cancer, urinary bladder cancer, and skin cancer are the most prevalent cancers in the United States. Breast cancer is predicted to be the most frequent type of cancer, with 284,200 cases, while lung and bronchus cancer are expected to be the leading causes of death, with 131,880 fatalities in 2021.

The flexibility of US government regulations and the availability of funds from various organisations, such as the National Institute of Health, has allowed researchers to invest more in the use of biomarkers in drug discovery, drug development, tumour detection, monitoring biological response to cancer therapy, and genetic studies for the identification of cancer-predisposed candidates.

Growth Factors

• The rising global prevalence of cancer:

According to the World Health Organization (WHO), cancer is a leading cause of death globally, accounting for nearly 10 million deaths in 2020. Between 30 and 50% of cancers can currently be prevented, and the cancer burden can also be reduced through early detection of cancer and appropriate treatment and care of patients who develop cancer. Many cancers have a high chance of being cured if detected early and treated properly. Therefore, the rising global prevalence of cancer will increase the demand for cancer profiling.

Restraints:

• Technical issues

One of the most immediate concerns regarding service providers is sample collection, which is followed by access to these samples. These samples must be subjected to strict quality control, and they must be maintained in the proper conditions to avoid loss. Furthermore, screening programmes are helpful for certain types of cancer but not others, and they are considerably more difficult and resource-intensive than early detection since they require specialised equipment and committed staff.

The Impact of COVID-19 on the Cancer Profiling Market:

The COVID-19 pandemic has affected the cancer profiling market. Due to the pandemic, there has been a considerable decrease in cancer testing and detection as a result of coronavirus-related measures and resources. Lockdowns imposed due to the pandemic have prompted fewer patients to go for health check-ups, severely straining the healthcare industry. However, some COVID-19 patients had cancer, so cancer has been recognised as a risk factor for COVID-19. Further studies in this area are being conducted in order to better understand the dynamics of the infection, which is likely to drive the cancer research field forward.

Competitive insight

• October 2021 - The Memorial Sloan Kettering tumour variant has been approved by the US Food and Drug Administration (FDA) for inclusion in its public human genetic variant database. The approach allows tumour profiling test makers to utilise the database to support clinical validity claims in regulatory applications.
• September 2021 - OncoDNA and SOPHiA GENETICS S.A. reached an agreement to make genomic profiling analysis and interpretation easier. According to the terms of the agreement, OncoDNA will adapt OncoKDM®, OncoDNA's interpretation platform, to be interoperable with SOPHiA GENETICS' AI-powered SOPHiA DDMTM platform.
• August 2021 - Tesis Labs, a pioneer in targeted genetic sequencing, and Personal Genome Diagnostics, Inc. (PGDx), a pioneer in cancer genomics, have partnered to harness the potential of genetic sequencing and analytics.

Market Segmentation

• By Technology

Immunohistochemistry

In situ Hybridization

Next-Generation Sequencing

Quantitative Polymerase Chain Reaction (qPCR)

Mass Spectrometry

Microarrays

Others

• By Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Melanoma Cancer

Kidney Cancer

Liver Cancer

Others

• By Application

Personalized Medicine

Oncological Diagnostics

Cancer Research

Biomarker Discovery

Treatment & Monitoring

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• UK
• Italy
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• South Africa
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porters Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Cancer Profiling Market Analysis, by Technology

• 5.1. Introduction
• 5.2. Immunohistochemistry
• 5.3. In situ Hybridization
• 5.4. Next-Generation Sequencing
• 5.5. Quantitative Polymerase Chain Reaction (qPCR)
• 5.6. Mass Spectrometry
• 5.7. Microarrays
• 5.8. Others

6. Global Cancer Profiling Market Analysis, by Cancer Type

• 6.1. Introduction
• 6.2. Breast Cancer
• 6.3. Lung Cancer
• 6.4. Colorectal Cancer
• 6.5. Prostate Cancer
• 6.6. Melanoma Cancer
• 6.7. Kidney Cancer
• 6.8. Liver Cancer
• 6.9. Others

7. Global Cancer Profiling Market Analysis, by Application

• 7.1. Introduction
• 7.2. Personalized Medicine
• 7.3. Oncological Diagnostics
• 7.4. Cancer Research
• 7.5. Biomarker Discovery
• 7.6. Treatment & Monitoring
• 7.7. Others

8. Global Cancer Profiling Market Analysis, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. UK
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. South Africa
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativenessness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

• 10.1. Illumina, Inc.
• 10.2. Qiagen N.V.
• 10.3. NeoGenomics Laboratories, Inc.
• 10.4. F. Hoffmann-La Roche Ltd
• 10.5. Genomic Health
• 10.6. GE Healthcare
• 10.7. Siemens Healthineers
• 10.8. Thermo Fisher Scientific Inc.
• 10.9. Hologic Inc.
• 10.10. Bio-Rad Laboratories Inc.